Different Regimens of Magnesium Sulphate in Patients With Severe Preeclampsia
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Preeclampsia (PE). Базовые параметры: от 18 лет · Женщины.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Египет
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Comparison of Different Regimens of Magnesium Sulphate in Patients With Severe Preeclampsia in Ain Shams University Maternity Hospital (Retrospective Cohort)
Обзор
The goal of this observational study is to learn about the effects of the different drug regimens of magnesium sulphate in treatment of (severe pre-eclampsia). This condition affects some pregnant women and raises their blood pressure. It may also cause seizures (fits). The medication (magnesium sulphate) helps to prevent seizures. The main question this study aims to answer is: What are the different regimens of magnesium sulphate that are used to prevent seizures in pregnant women with severe pre-eclampsia? Participants already have taken the magnesium sulphate as part of their regular medical care for severe pre-eclampsia. Researchers will look into the records of the participants in the past 5 years to collect the data.
Подробное описание
This will be a retrospective study describing the different regimens of MgSO4 used in patients diagnosed with SPE in Ain Shams University Maternity Hospital (ASUMH), and the occurrence of eclamptic fits and any other complications with each of them.
Methodology:
1. Protocol approval will be sought from ethical committee and hospital administration. 2. Screening of all hospital records over the past 5 years to identify eligible records. 3. Eligible records will be reviewed to extract the following data:
Age, Parity, Gestational age, BMI, Prior medical disorders, previous surgeries - including cesarean section (CS).
Data upon admission: (Blood pressure, albuminuria) Available labs (CBC, AST, ALT, serum creatinine, PTT, INR) Timing (since admission) and route of delivery. Regimen of MgSO4 used (loading and maintenance doses, the route, and total time of therapy - antepartum and postpartum); any changes in dosage, and the reason for change.
Any DOCUMENTED patient-reported MgSO4 side effects (nausea, vomiting, muscle weakness, palpitations, hypotension dizziness).
Any DOCUMENTED signs of magnesium toxicity (clinical: defined as a presence of respiratory depression with less than 16 respirations per minute or loss of deep tendon reflexes necessitating cessation of MgSO4 or administration of calcium gluconate and / or biochemical: serum magnesium level \>8.4mg/dl) Occurrence of eclamptic fits despite MgSO4 therapy, and timing, duration, how it was managed.
Maternal admission to intensive care unit (ICU). Other complications (pulmonary edema, postpartum hemorrhage) Neonatal ICU (NICU) admission.
All files with SPE will be examined. The number of files excluded from analysis will be noted as well as a table for the different causes of exclusion .
Files showing serum magnesium level will be also analyzed in more detailed tables together with the reasons behind checking the serum level. 4. Data will be recorded in a case report form (appendix 1) 5. Statistical analysis will be done accordingly.
Ethical Consideration:
* The study design will be approved by the Local Ethics committee, Faculty of Medicine, Ain Shams University. * Confidentiality will be respected in all levels of the study.
Первичные конечные точки
- Occurrence of eclamptic fits [Срок оценки: within 24 hours before or after delivery]
Вторичные конечные точки (3)
- ICU admission [Срок оценки: within 48 hours before or after delivery]
- magnesium sulphate toxicity [Срок оценки: within 48 hours before or after delivery]
- primary postpartum hemorrhage [Срок оценки: within 24 hours after delivery]
Критерии участия
Критерии включения
- All hospital records of patients diagnosed as preeclampsia with severe features planned to receive magnesium sulphate.
Критерии исключения
- Records with missing data about the regimen of magnesium sulphate used
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Египет · 1 центр
- Ain Shams University Maternity Hospital — Cairo
Идентификаторы
NCT: NCT06791668 · FMASU MS 619/2024